We recently published a list of 10 Best Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are going ...

BridgeBio Pharma (BBIO) stock in focus as its 2024 spinout BridgeBio Oncology merges with Helix to form go public on Nasdaq ...

The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have earned an average recommendation of “Moderate Buy” from the thirteen brokerages that are covering the firm, MarketBeat.com reports ...

BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its price target lifted by Citigroup from $45.00 to $49.00 in a research ...

For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. | For a while, special ...

But the direct-to-consumer ad didn't come from Palo Alto-based Bridge Bio (Nasdaq: BBIO); instead it was produced by Pfizer ...

BofA raised the firm’s price target on BridgeBio (BBIO) to $46 from $45 and keeps a Buy rating on the shares after accounting for the updated ...

One year after its initial public offering, Helix Acquisition Corp. II is now helping another biotech company go public.

In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against other best performing mid cap stocks to buy according to analysts. On February 7 ...

BridgeBio Pharma (BBIO) announces $500M convertible notes offering to repay debt, reduce interest expenses, and boost flexibility.